Shares of Athersys Inc. (NASDAQ:ATHX) shot up 3.6% during mid-day trading on Thursday . The stock traded as high as $2.04 and last traded at $2.02, with a volume of 353,171 shares traded. The stock had previously closed at $1.95.

Several brokerages have issued reports on ATHX. Maxim Group reissued a “buy” rating on shares of Athersys in a research note on Sunday, May 8th. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Monday, July 11th. Finally, TheStreet raised shares of Athersys from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st.

The stock’s market capitalization is $171.66 million. The stock has a 50 day moving average of $2.15 and a 200 day moving average of $2.11.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. The firm earned $0.60 million during the quarter, compared to analyst estimates of $0.32 million. The company’s revenue was up 200.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.05) EPS. On average, analysts forecast that Athersys Inc. will post ($0.21) EPS for the current year.

In other news, COO William Lehmann, Jr. sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $2.17, for a total transaction of $54,250.00. Following the completion of the sale, the chief operating officer now owns 279,017 shares of the company’s stock, valued at $605,466.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.